Swedish Orphan Biovitrum Net Cash Flow 2019-2024 | BIOVF

Swedish Orphan Biovitrum net cash flow for the twelve months ending September 30, 2024 was $-0.121B, a 38.79% decline year-over-year.

  • Swedish Orphan Biovitrum annual net cash flow for 2023 was $-0.043B, a 237.61% decline from 2022.
  • Swedish Orphan Biovitrum annual net cash flow for 2022 was $0.031B, a 58.1% decline from 2021.
  • Swedish Orphan Biovitrum annual net cash flow for 2021 was $0.075B, a 305.92% decline from 2020.

Swedish Orphan Biovitrum Net Cash Flow 2019-2024 | BIOVF

  • Swedish Orphan Biovitrum annual net cash flow for 2023 was $-0.043B, a 237.61% decline from 2022.
  • Swedish Orphan Biovitrum annual net cash flow for 2022 was $0.031B, a 58.1% decline from 2021.
  • Swedish Orphan Biovitrum annual net cash flow for 2021 was $0.075B, a 305.92% decline from 2020.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$218.1B
Amgen (AMGN)$157.3B
Gilead Sciences (GILD)$135.7B
Vertex Pharmaceuticals (VRTX)$119.2B
Bristol Myers Squibb (BMY)$94.5B
CSL (CSLLY)$78.8B
GSK (GSK)$77.4B
Regeneron Pharmaceuticals (REGN)$59.2B
Alnylam Pharmaceuticals (ALNY)$40.6B
Argenex SE (ARGX)$34B
BioNTech SE (BNTX)$26.6B
Royalty Pharma (RPRX)$20.5B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.7B
Illumina (ILMN)$15.4B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$13.6B
Incyte (INCY)$13.2B
Moderna (MRNA)$12.2B
Exelixis (EXEL)$12B
BioMarin Pharmaceutical (BMRN)$10.9B
Ascendis Pharma (ASND)$10.7B
QIAGEN (QGEN)$10.5B
Exact Sciences (EXAS)$10B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.4B
Bio-Techne Corp (TECH)$8.1B
Roivant Sciences (ROIV)$7.7B
Legend Biotech (LEGN)$7.3B
Revolution Medicines (RVMD)$7B